Asthma – Market Access and Reimbursement Insights Report – 2025

Asthma Market Access and Reimbursement Insights

Thelansis’s “Asthma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Asthma Overview

Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, caused by airway hyperresponsiveness and narrowing often triggered by allergens, infections, exercise, smoke, or environmental irritants. Affecting hundreds of millions of people worldwide, asthma is diagnosed based on clinical history, physical examination, and lung function tests, such as spirometry. It is commonly classified into several types: allergic, non-allergic, occupational, and exercise-induced. The management focuses on controlling symptoms and preventing exacerbations. Inhaled corticosteroids are the cornerstone of therapy and are often used in combination with long-acting beta-agonists. Short-acting beta-agonists are used as rescue medication when needed. For severe or uncontrolled disease, biologic therapies targeting immune pathways (anti‑IgE, anti‑IL‑5, anti‑IL‑4/13) provide advanced options, alongside trigger avoidance and regular monitoring. Prognosis is generally favorable with appropriate treatment, but poorly controlled asthma can lead to frequent exacerbations, hospitalizations, and even death, particularly in low‑ and middle‑income countries where under‑diagnosis and under‑treatment remain major challenges.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Asthma – Market Access and Reimbursement Insights Report – 2025